Erschienen in:
21.04.2017 | Original Article
Immunoprophylaxis of multi-antigen peptide (MAP) vaccine for human lymphatic filariasis
verfasst von:
Christiana Immanuel, Aparnaa Ramanathan, Malathi Balasubramaniyan, Vishal Kishor Khatri, Nitin Purushottam Amdare, Donthamsetty Nageswara Rao, Maryada Venkata Rami Reddy, Kaliraj Perumal
Erschienen in:
Immunologic Research
|
Ausgabe 3/2017
Einloggen, um Zugang zu erhalten
Abstract
Human lymphatic filariasis, the parasitic disease caused by the filarial nematodes Wuchereria bancrofti, Brugia malayi, and Brugia timori, is ranked as the second most complex clinical condition leading to permanent and long-term disability. The multiple antigen peptide (MAP) approach is an effective method to chemically synthesize and deliver multiple T and B cell epitopes as the constituents of a single immunogen. Here, we report on the design, chemical synthesis, and immunoprophylaxis of three epitopes that have been identified from promising vaccine candidates reported in our previous studies, constructed as MAP on an inert lysine core for human lymphatic filariasis in Jird model. Two epitopes from Thioredoxin and one epitope from Transglutaminase were constructed as MAP in an inert lysine core. The immunoprophylaxis of the synthetic vaccine construct studied in Jird models showed protective antibody (1 in 64,000 titer) and cellular immune response. Thioredoxin-Transglutaminase MAP (TT MAP) conferred a significantly high protection of 63.04% compared to control (8.5%). Multi-antigen peptide vaccine is one best approach to provide immunity against multiple antigens delivered by the complex filarial parasite.